CHMP recommends granting a marketing authorization for Santhera's Raxone® for the treatment of Leber's Hereditary Optic Neuropathy (LHON) Santhera Pharmaceuticals, 26 Jun 2015 Accessed on 30 Jun 2015 from http://www.santhera.com/index.php?docid=212&vid=&lang=en&newsdate=201506&newsid=1931735&newslang=en. CommentRecommendBookmarkWatch